The Group has eight products in the pipeline under development; they are mainly derived from peptides and microbiological sources. In relation to the research areas, CMS is primarily engaged in development of small molecular polypeptide, the microbiology product, oligonucleotide and antibiotic development focusing on therapeutic areas and major diseases in oncology, hepatic diseases, human immune system, and digestive system. Tyleuseuleutide (CMS024), one of our self-developed innovative products, obtained "Orphan Drug" status by US FDA in 2004, and has already passed technical examination by SFDA. It is our hope that this will be the first peptide for treatment of liver cancer in the world.

Through years' effort, CMS has gathered certain R&D professionals, both in pre-clinical research and clinical trials and established sizeable R&D bases, which combine the R&D platform of CMS with industrialized commercialization potential.As of 31 March 2007 our research and development team comprised of 60 research personnel and medical professionals with experience in the drug R&D field. Meanwhile, CMS has maintained collaborations with medical universities/colleges and research institutes in China.CMS also strives to seek opportunities to collaborate with Western research institutes, medical universities or small-medium sized biotechnology companies.